Premarket Decliner
INAB In8bio4.17+0.57+15.7%
Premarket:3.60-0.57 (-13.7%)
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
Globe NewswireMon, 9-Jun 7:00 AM
